Er-Kim and CNX Therapeutics Forge Groundbreaking Partnership

Author: Evelyn Baker Updated: 08-26-2025 05:13 AM

Groundbreaking Partnership Announcement

Er-Kim, an international pharmaceutical enterprise known for its expertise in novel therapies, has announced a significant partnership with CNX Therapeutics. This exclusive agreement focuses on distributing a selection of oncology products across Central and Eastern Europe (CEE) and Türkiye, marking a pivotal step for both companies.

Exclusive Distribution Agreement

The agreement positions Er-Kim as the exclusive distributor of CNX Therapeutics' oncology medication portfolio, which includes established products like Cardioxane and Savene. These treatments are set to enhance the oncology landscape across CEE, ensuring that patients have better access to essential therapies.

The Role of Er-Kim in Oncology

With over 40 years of experience in the pharmaceutical industry, Er-Kim has built a reputation as a trusted provider of oncology treatments within the region. Mert Zorlular, President & CFO of Er-Kim, expressed enthusiasm for this collaboration, highlighting the commitment to improving the quality of life for cancer patients through effective therapeutic solutions.

Strengthening Global Reach

This partnership not only enhances the portfolio available to healthcare providers but also allows CNX Therapeutics to tap into Er-Kim's well-established distribution network in Central and Eastern Europe. According to Pete Butterfield, Chief Operating Officer at CNX Therapeutics, the collaboration is a strategic move to broaden their market access and meet the needs of patients more effectively.

About Er-Kim

Founded in 1981, Er-Kim leads in biopharmaceutical innovation and commercialization. Partnered with over 40 global pharmaceutical leaders, Er-Kim's portfolio includes more than 68 products distributed across over 50 countries, showing their commitment to overcoming international healthcare challenges. The company boasts a dedicated workforce of over 300 professionals and impressive annual revenues exceeding EUR 305 million.

About CNX Therapeutics

CNX Therapeutics is committed to improving patient lives through access to essential medications. This specialty pharmaceutical company focuses on a range of therapeutic areas across over 60 markets worldwide. Their portfolio includes solutions for neurological, psychiatric, and critical care scenarios, positioning them as a key player in the global pharmaceutical landscape.

Contact Information

For media inquiries regarding this significant partnership, please contact:

Rosalia Scampoli
Marketcom PR
Tel: (914) 815-1465
Email: rscampoli@marketcompr.com

Mehdi Juma
CNX Communications Manager
Email: mehdi.juma@cnx-therapeutics.com

Frequently Asked Questions

What is the nature of the partnership between Er-Kim and CNX Therapeutics?

Er-Kim and CNX Therapeutics have entered into an exclusive agreement to distribute oncology products across Central and Eastern Europe and Türkiye.

What products will be included in this distribution agreement?

The agreement includes oncology medications such as Cardioxane and Savene from CNX Therapeutics' established portfolio.

When was Er-Kim founded?

Er-Kim was established in 1981 and has become a leader in biopharmaceutical innovation.

How many professionals does Er-Kim employ?

Er-Kim has a dedicated team of over 300 professionals working globally.

What is CNX Therapeutics' focus area?

CNX Therapeutics specializes in providing essential medicines for neurological, psychiatric, and critical care, with a commitment to ethical standards and sustainability.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.